International AIDS Society

Study results support early treatment, even in patients with a high CD4 count.

Researchers discussed new HIV vaccine developments in protecting antibodies capable of neutralizing many different strains of the virus and reviewed the comorbidity of HIV and hepatitis C virus (HCV).

HIV-infected patients face increased risk of myocardial infarction, as well as higher risk for ART-associated dyslipidemia and insulin resistance.

A panel of experts discuss information from late-breaking abstracts presented at IAS 2013, including information on the two patients who remain HIV-free following stem cell transplant.

Two male patients with prolonged HIV infection who received hematopoietic stem cell transplants still remain virus-free several consecutive weeks after their antiretroviral treatments were discontinued this spring.

Panel discussion of study results presented at IAS 2013 focusing on strategies for using antiretroviral therapy (ART) in patients with HIV who are ART-naïve or who have failed previous therapies.

A new report says a broader base of funders committed to sustained support of HIV prevention research is need to ensure continued progress in the fight to end the AIDS epidemic.

As pre-exposure prophylaxis (PrEP) remains at the forefront of HIV prevention research, clinical trial investigators provided an update on recent oral and topical PrEP efficacy studies at the second plenary session of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), held June 30 to July 3 in Kuala Lumpur, Malaysia.

Consolidated guidelines from the World Health Organization recommend starting treatment when a patient's CD4 count falls below 500, and also recommend a new first-line ART regimen.

News and updates about the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).